Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787799 | 0.83 | POLB (0.53) | GAAPOLBALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL7257046 | 0.76 | ALDH1A1 (0.52) | GAAHTTPOLBALDH1A1CYP1A2 | |
| SCHEMBL5569535 | 0.73 | POLB (0.58) | GAAHTTPOLBALDH1A1CYP1A2 | |
| SCHEMBL4640360 | 0.72 | CYP1A1 (0.49) | POLBCYP1A2L3MBTL1 | |
| SCHEMBL7257043 | 0.72 | ALDH1A1 (0.52) | GAAHTTPOLBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7257896 | 0.72 | POLB (0.57) | GAAHTTPOLBALDH1A1CYP1A2 | |
| SCHEMBL5573131 | 0.72 | ALDH1A1 (0.52) | GAAHTTPOLBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL5572582 | 0.71 | ALDH1A1 (0.51) | GAAHTTPOLBALDH1A1CYP1A2 | |
| SCHEMBL4116440 | 0.69 | CYP2C9 (0.55) | HTTALDH1A1CYP1A2L3MBTL1KMT2A | |
| SCHEMBL5574086 | 0.69 | POLB (0.49) | GAAHTTPOLBALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057815-B1 | CYCLIC AMIDE COMPOUNDS | KOWA CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6645957-B2 | Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis | KOWA CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20030096828-A1 | Cyclic amide compound | KOWA CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-6448242-B1 | COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS | KOWA CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-1057815-A1 | CYCLIC AMIDE COMPOUNDS | Kowa Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096828-A1 | Cyclic amide compound | CMA1, HRH2, HRH4 | GAA 1982/4885HTT 4814/4885POLB 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.